This SDD technology will improve the bioavailability of compounds with low aqueous solubility.
Bend Research will continue to provide formulation, development, analytical, engineering and manufacturing services to Lilly to support its preclinical and clinical development programs.
Bend Research CEO Rod Ray said they believe this collaboration will add significant value to Lilly’s research efforts and help them advance their compounds more quickly and efficiently.
"Our teams work well together and have a shared commitment to bring the best new medicines to caregivers and patients," Ray added.